Evidence map›Paper›PMID 42493511›Full record

ArticleNature communications2026

Acute rapamycin treatment reveals distinct mechanisms of dysfunction in a maternal inflammation mouse model.

J E Le Belle, M C Condro, C Cepeda, K D Oikonomou, K Tessema, L Dudley, J Schoenfield, R Kawaguchi, D Geschwind, A J Silva and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

J E Le BelleSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
M C CondroSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
C CepedaSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
K D OikonomouSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
K TessemaSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.ORCID 0000-0001-5204-3457
L DudleySemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
J SchoenfieldThe UCLA Brain Injury Research Center, Department of Neurosurgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.ORCID 0009-0008-6399-6542
R KawaguchiSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.ORCID 0000-0002-2489-4825
D GeschwindSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-2896-3450
A J SilvaDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Z ZhangDepartment of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, CA, USA.ORCID 0000-0003-0541-7211
K ShokatDepartment of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, CA, USA.ORCID 0000-0001-8590-7741
N G HarrisThe UCLA Brain Injury Research Center, Department of Neurosurgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. ngharris@ucla.edu.ORCID 0000-0002-1965-6750
H I KornblumSemel Institute for Neuroscience & Human Behavior, Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. hkornblum@mednet.ucla.edu.ORCID 0000-0002-3779-4540

Funding

UCLA IDDRC: Translational CoreP50HD103557 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Peyman Golshani, SUMA JACOB · 2020 to 2026
$9.6M
Strategy to Potentiate Rehabilitation after TBIR01NS116383 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HARRIS, NEIL · 2021 to 2025
$3.0M
Predictive accuracy of acute astroglial compromise biomarkers after traumatic brain injuryUG3NS106945 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HARRIS, NEIL, WANNER, INA BEATE · 2018 to 2020
$882k
Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) DRG-2281-17NICHD NIH HHS P50 HD103557NINDS NIH HHS R01 NS116383NINDS NIH HHS UG3 NS106945Simons Foundation SFI-AN-AR-Cross Species-00005172U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HD103557U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH12205U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) UG3NS106945, NS09122, NS116383
6 · The paper itself

Abstract

Maternal inflammatory response (MIR) during early mouse gestation induces a cascade of physiological and behavioral changes associated with autism spectrum disorder (ASD). We have shown that mild MIR causes chronic systemic and brain inflammation, mTOR pathway activation, mild brain overgrowth with regionally specific volumetric changes, sensory processing dysregulation, and repetitive behavior abnormalities. Prior rapamycin studies in autism models focused on chronic treatments that alter or prevent physical brain changes. Here, we focus on acute rapamycin effects to uncover novel mTOR pathway-mediated mechanisms of dysfunction. Within 2 hours, rapamycin rescues neuronal hyperexcitability, seizure susceptibility, functional network connectivity, brain community structure, repetitive behaviors, and sensory over-responsivity in adult MIR offspring. These CNS-mediated effects coincide with altered expression of genes associated with ASD, ion channels, and epilepsy. Our findings demonstrate that mTOR dysregulation drives dysfunctional brain development in MIR offspring but the adult brain remains amenable to rapid functional normalization, rescuing core and comorbid ASD-associated brain and behavior phenotypes. Restoring excitatory/inhibitory imbalance and sensory functional network modularity may be important targets for therapeutically addressing multiple ASD phenotypes.

Indexed as

Autism Spectrum DisorderInflammationPrenatal Exposure Delayed EffectsSirolimusAnimalsBehavior, AnimalBrainDisease Models, AnimalFemaleMaleMiceMice, Inbred C57BLPregnancySignal TransductionTOR Serine-Threonine KinasesmTOR protein, mouseSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID42493511
PMCPMC13396360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.